Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lefunomide in combination therapy.

Joachim R Kalden1, Josef S Smolen, Paul Emery

  • 1Department of Internal Medicine III, Universitaet Erlangen-Nuremberg, Erlangen, Germany. joachim.kalden@med3.med.uni-erlangen.de

The Journal of Rheumatology. Supplement
|June 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025.

Annals of the rheumatic diseases·2026
Same author

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024.

Annals of the rheumatic diseases·2025
Same author

Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.

Annals of the rheumatic diseases·2023
Same author

[80 milestones in rheumatology from 80 years- III. 1980-2000].

Zeitschrift fur Rheumatologie·2021
Same author

Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD.

RMD open·2019
Same author

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

RMD open·2019
Same journal

GRAPPA 2019 Research Recipient Awards Report.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA 2020 Update From the Education Committee.

The Journal of rheumatology. Supplement·2021
Same journal

The Role of Ultrasound in Research and Clinical Practice in Psoriatic Arthritis: Highlights From the GRAPPA Ultrasound Workshop.

The Journal of rheumatology. Supplement·2021
See all related articles

Leflunomide is effective and well-tolerated for rheumatoid arthritis (RA) when used with sulfasalazine or methotrexate (MTX). Combination therapy with leflunomide shows promise in RA treatment, but careful patient monitoring is essential.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Methotrexate (MTX) is a common initial treatment for rheumatoid arthritis (RA).
  • Patients often require additional agents when MTX therapy fails.
  • Leflunomide is an alternative disease-modifying antirheumatic drug (DMARD).

Purpose of the Study:

  • To review the efficacy and tolerability of leflunomide in combination therapy for RA.
  • To assess expert opinion on leflunomide combination regimens.
  • To identify potential areas for future research in leflunomide combination therapy.

Main Methods:

  • Review of clinical studies on leflunomide combination therapy.
  • Analysis of expert panel opinions from an international meeting.
  • Evaluation of leflunomide's use with various DMARDs and biological agents.

Related Experiment Videos

Main Results:

  • Leflunomide is clinically efficacious and well-tolerated with sulfasalazine or MTX for RA.
  • Expert panel indicated willingness to combine leflunomide with various agents, including MTX, sulfasalazine, and biologics like infliximab.
  • Combination of leflunomide and infliximab suggested for further investigation in a controlled trial.

Conclusions:

  • Combination therapy with leflunomide is a viable option for rheumatoid arthritis treatment.
  • Careful patient monitoring is crucial when implementing leflunomide combination therapies.
  • Further prospective studies are warranted for specific leflunomide combination regimens, particularly with infliximab.